Lyophilization services: how to choose a contract lyophilization CMO, and what to send them

Contract lyophilization looks like a commodity from the outside: you send material, you get vials back. In practice the outcome depends on what you send, how the CMO turns your formulation into a cycle on its own dryer, and how the sterile steps around the dryer are controlled. This guide is for buyers comparing lyophilization services, freeze drying services or a lyophilization CMO for peptides and biosimilars. It covers the tech-transfer package, cycle development and scale-up, batch and vial formats, release testing, what drives timelines, the questions to ask, and the bring-your-own-peptide model.

It assumes the basics of freeze-drying; for those, start with what is a lyophilized peptide and the peptide lyophilization guide. The sterile process is covered in aseptic fill finish explained.

What do lyophilization services include?

“Lyophilization services” covers two different jobs. The first is drying bulk material: EMA’s synthetic peptides guideline notes that “lyophilisation of synthetic peptides is considered common practice” for isolating the active substance, alongside precipitation, crystallisation and spray drying [1]. The second, and the subject of this guide, is drug-product lyophilization in vials, where each vial is filled, dried, closed and released as a sterile unit. Under EU GMP Annex 1 that work is “a critical process step” and an extension of aseptic processing [2].

A full-scope drug-product service typically includes:

Stage	What the CMO does	Main output
Feasibility and tech transfer	Reviews your documents, gaps and risks	Transfer plan and gap analysis [3]
Formulation and thermal characterisation	Measures the critical (collapse) temperature, for example by DSC or freeze-drying microscopy	Target product temperature [4]
Cycle development	Defines freezing, primary and secondary drying set points for your vial and fill	Draft cycle and design space [5]
Engineering or pilot batch	Runs the cycle on the production dryer with placebo or product	Scale-up data, sampling results [6]
GMP batches	Sterile filtration, aseptic filling, lyophilization, stoppering, capping, inspection	Filled, sealed vials and batch record [2]
Testing and release support	Coordinates QC testing and documentation	Certificate of analysis and batch documentation [7]

What to send: the tech-transfer package

WHO defines technology transfer as “a logical procedure involving the transfer of products, processes and knowledge, supported by relevant documentation and professional expertise”, between a sending unit and a receiving unit [3]. It expects a documented project plan, a quality risk management plan and “a comprehensive gap analysis, including due diligence performed covering technical, quality and regulatory aspects” [3]. The documents WHO lists as commonly required map closely onto a lyophilization project:

Area	What to send	Why the CMO needs it
Active substance	Specifications, safety data sheet, storage conditions, stability and forced stability data, master file reference if any [3]; certificate of analysis	Incoming testing, handling, hold times
Formulation	Composition, formulation development report, compatibility data [3]	Compounding instructions and filter selection
Thermal data	Collapse temperature, Tg′ or eutectic temperature, method used [4]	Sets the target product temperature
Existing process	Any lab or clinical cycle, batch records, scale-up information, critical process parameters [3]	Starting point for cycle transfer
Analytics	Analytical procedures and their validation status [3]	Method transfer before release testing
Presentation	Target quantity per vial, fill volume, vial and stopper type, batch quantity	Cycle design, line set-up, component sourcing
Regulatory context	Regulatory process description and applicable regulatory documentation [3]; intended use (research or regulated product) and market	Which GMP standard and documentation apply

Thermal data is the item most often missing. Practical guidance notes that the critical product temperature “can be measured in many cases by FDM and/or DSC”, and recommends confirming it by running cycles with the product in vials at the target fill volume, because the product “could tolerate product temperature higher than per FDM/DSC measurements” [4]. For sterile filtration, the CMO will also want to validate bacterial retention with your actual product where possible [2] [8], so send enough material for filter studies.

Cycle development and scale-up

Cycle development starts from one number. “The critical first step in establishing primary drying conditions is selecting the target product temperature, commonly chosen as 2°C below the critical product temperature”, after which shelf temperature and chamber pressure combinations are mapped into a design space [4]. The LyoHUB best-practice papers describe this design-space approach in detail, built from first principles and the vial heat transfer coefficient (Kv), which “differs from container to container and is dependent on the chamber pressure” [5].

Scale-up is where projects fail. A 2022 multi-company review found that “using the same process set points/times in laboratory and commercial scale dryers may lead to loss of product quality (collapse or vial breakage)”, and that modelling needs “the upfront generation of some input parameters (vial heat transfer coefficient, minimum controllable pressure, and maximum sublimation rate)” [9]. Its conclusion is useful for buyers: primary drying “can be transferred with a high degree of confidence”, secondary drying “is usually fairly straightforward”, but “predicting potential changes in product behavior during freezing remains challenging” [9]. The second part summarises the scale-up challenges the series covers: vial breakage during freezing at commercial scale, differences in cake resistance between scales, and the effect of differences in refrigeration capacity and dryer geometry [10]. The LyoHUB authors add that a design space built on a lab dryer “cannot be directly applied to commercial-scale lyophilizer” without adjusting Kv, product resistance and minimum controllable pressure [5].

Freezing technology can change the economics. In one laboratory comparison for a 5% sucrose formulation, controlled ice nucleation reduced processing time “by as much as 25 h” [5]. Whether that applies to your product and the CMO’s dryer is a question to ask, not an assumption.

Peptide-specific points to raise

Peptides bring a few issues that a general lyophilization CMO may not raise unprompted:

• Hygroscopic, sensitive starting material. EMA’s synthetic peptides guideline asks that manufacturing processes “take into account any special characteristics such as hygroscopicity of (lyophilised) active substance, as well as any temperature and/or light sensitivity” [1]. Agree how the CMO will store, equilibrate and weigh your bulk peptide.
• Dispensing correction factors. The same guideline notes that correction factors may be applied during dispensing, “based on assay, purity, moisture content, residual solvent content, and/or salt content of active substance”, to reach the declared content [1]. Your certificate of analysis needs to carry those values, and both sides should agree the calculation.
• Filter adsorption. Annex 1 requires that “adsorption of product components and extraction/leaching of filter components should be evaluated” when the filtration system is selected [2].

Batch sizes and vial formats

Batch size in lyophilization is set by the dryer, not just the filling line. LyoHUB guidance explains that “minimum and maximum batch sizes for lyophilized products are defined in terms of the shelf load”; for a 10-shelf dryer, a minimum batch might be one shelf and a maximum ten [6]. The maximum is constrained twice: cycle parameters must generate “a vapor flux that can be supported by the lyophilizers at the maximum batch size”, and “total net water to be removed is always below condenser capacity” [6]. The maximum load also amplifies “center to edge vial Kv differences” [6], which is why edge vials run warmer and cycle margins are set for them.

Vial format is a project decision with cycle consequences. Fill depth matters: fill heights above 2 cm are described as undesirable, and deeper fills need a freezing hold extended beyond two hours [4]. Under Annex 1, adding a new container-closure combination triggers a repeat of the initial aseptic validation, although Annex 1 allows bracketing “for validation of the same container/closure configuration for different products where process equivalence is scientifically justified” [2]. The scale-up review also gives recommendations on the residual vacuum to leave in vials across a wide range of vial capacities [10]. Ask the CMO which vial sizes, stopper types and fill ranges its line and dryer are already qualified for; staying within them shortens the project.

Validation: engineering runs, PPQ and what gets tested

FDA describes process validation in three stages: process design, in which the commercial process “is defined during this stage based on knowledge gained through development and scale-up activities”; process qualification; and continued process verification [11]. For lyophilization, process qualification “has historically relied on the three-drug product lot validation for a given cycle and dose”, with expanded sampling for the attributes most affected by drying [6]. LyoHUB’s member survey found that “the most common critical quality attributes (CQAs) tested by the member companies were visual appearance, residual moisture, potency, and reconstitution time” [6]. Engineering batches before qualification also reveal loading effects; one case study recorded reject rates of 20.0% on some shelves when vials were indexed during loading, against 0.2% to 0.9% with fully indexed shelves [6].

QC release tests for lyophilized vials

Test	Purpose	Basis
Visual appearance of cake	Collapse, meltback, shrinkage, foreign matter	Common lyophilization CQA [6]
100% visual inspection	Every filled container checked for contamination or defects	Annex 1 clause 8.30 [2]
Identity, assay, purity	Product quality after drying	Potency is a common lyophilization CQA [6]
Residual moisture	Dryness and stability	Common lyophilization CQA [6]
Reconstitution time	Cake performance	Common lyophilization CQA [6]
Sterility	Required for products purporting to be sterile	21 CFR 211.167(a) [7]
Bacterial endotoxins	Required for products purporting to be pyrogen-free	21 CFR 211.167(a) [7]
Pre-filtration bioburden	Each batch, before the final sterilising filter	Annex 1 clause 10.3 [2]
Vacuum maintenance / container closure integrity	Vials sealed under vacuum must hold it before release and on stability	Annex 1 clause 8.24 [2]
Lyophilizer vent filter integrity	Result forms part of batch certification	Annex 1 clause 8.124 [2]

Container closure integrity needs a validated method. Industry experts report “no gold standard for CCI test methods” [12]; validated options for freeze-dried vials include vacuum decay, which detected laser-drilled holes of about 5 µm and above [13], and headspace oxygen analysis, which detected 0.2 µm leaks within hours of stoppering [14]. The LyoHUB protocol guidance also lists residual moisture and headspace oxygen as in-process characterisation tests [6]. For the analytical side, see peptide purity testing by HPLC and MS and endotoxin testing for peptides.

What drives the timeline

Lead times vary by CMO and product, so be wary of a fixed number quoted before the CMO has seen your data. The drivers are predictable:

• Completeness of the transfer package. Gaps in thermal data, methods or stability data add development runs [3] [4].
• Analytical method transfer. Release testing cannot start until the methods are transferred or verified at the testing laboratory [3].
• Cycle length and dryer scheduling. Each development or engineering run occupies the dryer for the full cycle, and conservative conditions for formulations with low critical temperatures “often lead to longer than desired processing times” [5].
• Line readiness. Aseptic lines need current media-fill coverage for the container and shift; Annex 1 expects repeat simulations about every six months, and a new container-closure combination can trigger revalidation [2].
• Release testing. Sterility, endotoxin and CCI testing run after the batch is made; FDA’s aseptic guidance gives separate sections to sterility testing and to the investigation of sterility positives [15].

Questions to ask a lyophilization CMO

Question	What a good answer shows
What thermal data do you need, and will you confirm the critical temperature in vials?	Science-led cycle design [4]
How do you transfer a cycle between dryers? Do you have Kv and minimum controllable pressure data for your production dryer?	Modelling-based scale-up [5] [9]
What are your dryer’s minimum and maximum loads and condenser capacity?	Realistic batch sizing [6]
Which vials, stoppers and fill ranges are already qualified on your line?	Shorter set-up [2]
How is the lyophilizer sterilised and loaded, and how often is the leak rate checked?	Annex 1 clauses 8.122–8.126 in practice [2]
What are your recent media-fill results for this line and container?	Current aseptic assurance [2]
How do you validate sterile filtration with my product, and do you perform PUPSIT?	Filter control [2] [8]
Which CCI method do you use, and what is its detection limit?	Defensible integrity data [12]
Which tests are done in-house and which are subcontracted?	Clear testing chain [16]
Will any step be subcontracted to another site?	Transparency required by EU GMP [16]
Who owns the cycle, the batch records and the development report?	Freedom to transfer later
Which GMP certificates cover the site that will do the work?	Fit to your market; see WHO-GMP certification explained

Contracts and quality agreements

EU GMP Chapter 7 sets the baseline for any outsourced GMP activity. “There must be a written Contract between the Contract Giver and the Contract Acceptor which clearly establishes the duties of each party” [16]. Before outsourcing, “the Contract Giver is responsible for assessing the legality, suitability and the competence of the Contract Acceptor” (7.5) [16]. The contract acceptor “should not subcontract to a third party any of the work entrusted to him under the Contract without the Contract Giver’s prior evaluation and approval of the arrangements” (7.11), and the contract “should permit the Contract Giver to audit outsourced activities” (7.17) [16]. Annex 1 adds that the site’s contamination control strategy should cover “management of outsourced activities and availability/transfer of critical information between parties” [2]. The broader CMO, CDMO and CRDMO comparison is in CDMO vs CMO vs CRDMO.

The bring-your-own-peptide model

Many buyers already have a peptide, from in-house synthesis or another supplier, and only need it dried and filled. In that model the buyer is the source of the active substance, so the transfer package above becomes the buyer’s responsibility, and the CMO’s incoming testing confirms identity and quality against your specification. Agree in advance on what happens if the material fails incoming testing, how much overage is needed for filter studies and line losses (LyoHUB discusses “batch size overage to compensate for losses during production” [6]), and whether the vials are labelled for research use or made for a regulated product, because that decides the documentation set.

How Winhycare Pharma handles lyophilization projects

Winhycare Pharma offers lyophilisation and vial filling of peptides and biosimilars at WHO-GMP certified manufacturing partners in India, with projects managed from Hyderabad. The service covers cycle development and optimisation, engineering, pilot and commercial batches, residual moisture and reconstitution optimisation, stoppering, crimp sealing and packaging, and coordination of analytical testing and documentation. Clients can bring their own peptide for a standalone project. Batch sizes and vial configurations are defined per project, and partner process details are shared per project. Commercial processing of approved products is subject to the applicable regulatory approvals, manufacturing licences and site authorisations.

See peptide lyophilisation services, biosimilar lyophilisation or, for European clients, lyophilisation for Europe. To start, send a lyophilisation enquiry with the items from the tech-transfer table above.

Research peptides supplied by Winhycare Pharma are for laboratory research use only. Not for human or veterinary use.